Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

NCT06414915 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Surufatinib
DRUG: Tislelizumab

Sponsor

National Cancer Center, China